

Supplementary Table 1. Education control group content (parents and teens)

| Session | Topics covered | Sources |
|---------|---|---|
| 1 | Difference between acute and chronic pain | www.webmap2.com |
| 2 | Pain assessment; Pain treatment | www.webmd.com www.aboutkidshealth.ca |
| 3 | Causes of chronic pain | www.med.umich.edu www.aboutkidshealth.ca |
| 4 | Overview of six different pain conditions | http://kidshealth.org www.webmd.com www.drugs.com http://orthoinfo.aaos.org http://my.clevelandclinic.org www.fibromyalgia-symptoms.org |
| 5 | Transmission of pain messages: pain and the brain | www.aboutkidshealth.ca |
| 6 | Chronic pain management; disparities in pain | http://chapinandrussell.com www.aboutkidshealth.org/ca www.nationalpainfoundation.org |
| 7 | Pain as a public health problem | http://health.yahoo.net www.webmd.com |
| 8 | Myths about pain; parenting a child with pain | www.aboutkidshealth.ca www.nationalpainfoundation.org |

Supplementary Table 2. Standardized regression coefficients (β), standard errors, and statistical significance for the full linear mixed effects models predicting GI symptoms, abdominal pain, and pain interference

| | <i>Treatment Outcome</i> | | |
|--|----------------------------|-------------------------------|----------------------------------|
| | GI Symptoms $\beta(SE)$ | Abdominal Pain $\beta(SE)$ | Pain Interference $\beta(SE)$ |
| Constant | 0.09 (0.26) | 0.87*** (0.31) | 43.96*** (3.05) |
| Age | 0.06*** (0.02) | 0.03 (0.02) | -0.04 (0.20) |
| Male | 0.01 (0.04) | 0.08* (0.04) | 1.20** (0.41) |
| Piece 1 | -0.02*** (0.01) | -0.03*** (0.01) | 0.01 (0.08) |
| Piece 2 | 0.003 (0.003) | -0.002 (0.004) | -0.07* (0.04) |
| Treatment (reference group = EDU) | -0.08 (0.08) | -0.09 (0.10) | 0.47 (0.98) |
| FAP Subgroup (reference group = LPA) | | | |
| HPD | 1.06*** (0.10) | 1.32*** (0.12) | 13.58*** (1.25) |
| HPA | 0.51*** (0.10) | 0.85*** (0.12) | 7.10*** (1.21) |
| Treatment (reference group = EDU) x Time | | | |
| CBT x Piece 1 | 0.01 (0.01) | 0.01 (0.01) | 0.05 (0.08) |
| CBT x Piece 2 | -0.001 (0.003) | -0.004 (0.004) | -0.04 (0.04) |
| FAP Subgroup (reference group = LPA) x Time | | | |
| HPD x Piece 1 | -0.02** (0.01) | -0.03** (0.01) | -0.28** (0.10) |
| HPD x Piece 2 | -0.01 (0.003) | -0.01 (0.005) | 0.01 (0.04) |
| HPA x Piece 1 | -0.01 (0.01) | -0.02* (0.01) | -0.22* (0.10) |
| HPA x Piece 2 | -0.003 (0.003) | -0.001 (0.005) | 0.06 (0.04) |

Treatment (reference group = EDU) x FAP Subgroup (reference group = LPA)

| | | | |
|-----------|------------------|----------------|-----------------|
| CBT x HPD | 0.24** (0.10) | 0.06 (0.12) | -0.51 (1.20) |
| CBT x HPA | 0.09 (0.10) | 0.17 (0.12) | 0.30 (1.19) |

Treatment (reference group = EDU) x FAP Subgroup (reference group = LPA) x Time

| | | | |
|---------------------|--------------------|--------------------|-----------------|
| CBT x HPD x Piece 1 | -0.02** (0.01) | -0.02* (0.01) | -0.09 (0.10) |
| CBT x HPD x Piece 2 | -0.0003 (0.003) | 0.01 (0.005) | 0.04 (0.04) |
| CBT x HPA x Piece 1 | -0.01 (0.01) | -0.02 (0.01) | -0.06 (0.10) |
| CBT x HPA x Piece 2 | -0.0000 (0.003) | -0.0002 (0.005) | 0.02 (0.04) |

| | | | |
|----------------------------|-----------|-----------|-----------|
| Observations | 1,143 | 1,134 | 1,140 |
| Log Likelihood | -1,061.80 | -1,366.99 | -3,898.74 |
| Akaike Inf. Crit. | 2,173.61 | 2,783.98 | 7,847.49 |
| Bayesian Inf. Crit. | 2,299.20 | 2,909.38 | 7,973.01 |
| Marginal R ² | 0.26 | 0.28 | 0.25 |
| Conditional R ² | 0.71 | 0.67 | 0.64 |

Note:

*p<0.05; **p<0.01; ***p<0.001

The coefficient of determination (R^2) reflects the total variance in the outcome variable explained by the predictors in each model. Marginal and conditional R^2 values for mixed models are calculated based on Nakagawa et al., (2017)¹⁸ where the marginal R^2 considers only the variance of fixed effects and the conditional R^2 considers both fixed and random effects.

Supplementary Table 3. Means and standard deviations (SDs) for outcome measures across timepoints by treatment condition

| | | Treatment Period (Piece 1) | | Follow-up Period (Piece 2) | | |
|--------------------------|---------------------|----------------------------|-------------------|----------------------------|-----------------|------------------|
| Outcome | Treatment Condition | T0: Baseline | T1: Mid-Treatment | T2: Post-Treatment | T3: 6-month FU | T4: 12-month FU |
| GI Symptoms | CBT | 1.63 (0.77) | 1.21 (0.76) | 1.09 (0.68) | 0.94 (0.74) | 0.96 (0.78) |
| | EDU | 1.57 (0.73) | 1.30 (0.79) | 1.14 (0.79) | 1.10 (0.79) | 1.10 (0.84) |
| Abdominal Pain | CBT | 2.24 (0.86) | 1.70 (0.77) | 1.48 (0.90) | 1.22 (0.94) | 1.17 (1.00) |
| | EDU | 2.27 (0.93) | 1.90 (0.99) | 1.55 (1.02) | 1.50 (0.99) | 1.37 (1.05) |
| Pain Interference | CBT | 52.00 (8.34) | 51.45 (9.83) | 49.11 (8.87) | 47.72 (9.46) | 46.59 (10.30) |
| | EDU | 51.68 (8.67) | 51.00 (10.25) | 48.90 (9.29) | 48.64 (9.79) | 47.90 (9.91) |

Scores for Children's Somatic Symptoms Inventory (GI Symptoms) and Abdominal Pain Index were normalized to a 4-point scale. The PROMIS Pain Interference is presented using T Scores.